• Marco Valgimigli, Gianluca Campo, Nicoletta de Cesare, Pascal Vranckx, Martial Hamon, Dominick J Angiolillo, Manel Sabatè, Fabrizio Ferrari, Alessandro Furgieri, Carlo Tumscitz, Alessandra Repetto, Salvatore Colangelo, Emanuele Meliga, Moh'd Kubbajeh, Giovanni Parrinello, Gianfranco Percoco, and Roberto Ferrari.
• University of Ferrara, Cardiovascular Institute, Arcispedale S. Anna Hospital, Corso Giovecca 203, 44100 Ferrara, Italy. vlgmrc@unife.it
• Cardiovasc Drugs Ther. 2008 Aug 1; 22 (4): 313-20.

PurposeTo assess whether glycoprotein IIb/IIIa inhibition using tirofiban in low risk patients undergoing percutaneous coronary intervention (PCI) may reduce the risk of periprocedural myocardial infarction compared to standard care in poor responders to aspirin and/or clopidogrel.MethodsWe will enroll patients at ten European sites or more to participate in the Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin and/or Resistance to clopidogrel (3T/2R) study with a pre-specified sample size of 240 patients out of 1,100 or more who will undergo screening. The primary outcome measure is troponin I or T elevation ratio at least three times the upper limit of normal within 48 h after completion of the PCI.ConclusionThe results of 3T/2R study will evaluate whether tailored intensification of anti-platelet treatment based on poor individual response to oral anti-platelet agents may modulate the risk of periprocedural myocardial infarction during PCI. Our findings attempt at unraveling a new era of individualized anti-platelet treatment through the use of point-of-care assessment.

30 keywords...

hide…